This nonprofit is playing a valuable role in framing the drug price discussion
This weekly column offers opinions on the latest pharmaceutical industry news.
For the past two years, the Institute for Clinical and Economic Review has issued high-profile reports assessing the worth of pricey new drugs for treating hepatitis C and high cholesterol, among other conditions
ICER has actually been assessing health care costs for about a decade, but only began evaluating drugs two years ago when new hepatitis C treatments suddenly emerged.
Ever since that episode, some of its methodology has been questioned...
Continue reading....
No comments:
Post a Comment